Filing Flows › Bio-Rad Laboratories (BIO) › Clinical Diagnostics revenue
Bio-Rad Laboratories (BIO) Clinical Diagnostics revenue by quarter
Bio-Rad Laboratories' Clinical Diagnostics revenue was $402M in Q3 2026 (third quarter 2026), +0.7% from Q2 2026. Over the last 7 quarters it ranged from $357M (Q1 2025) to $425M (Q4 2025).
| Quarter | Clinical Diagnostics revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $402M | +0.7% | +3% |
| Q2 2026 | $399M | +10% | +3% |
| Q1 2026 | $364M | -15% | +2% |
| Q4 2025 | $425M | +9% | — |
| Q3 2025 | $391M | +0.6% | — |
| Q2 2025 | $389M | +9% | — |
| Q1 2025 | $357M | — | — |
Q3 2026 at a glance
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bio-Rad Laboratories' Clinical Diagnostics revenue?
Bio-Rad Laboratories' Clinical Diagnostics revenue was $402M in Q3 2026 (third quarter 2026), +0.7% from Q2 2026.
How has Bio-Rad Laboratories' Clinical Diagnostics revenue changed?
Over the last 7 quarters it ranged from $357M (Q1 2025) to $425M (Q4 2025).